​

Seres Therapeutics (MCRB) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

MCRB Stock Forecast

Seres Therapeutics (MCRB) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $1.25, with a high of $1.25 and a low of $1.25. This represents a -92.72% decline from the last price of $17.17.

- $4 $8 $12 $16 $20 High: $1.25 Avg: $1.25 Low: $1.25 Last Closed Price: $17.17

MCRB Stock Rating

Seres Therapeutics stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (61.11%), 3 Hold (16.67%), 4 Sell (22.22%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 4 3 11 Strong Sell Sell Hold Buy Strong Buy

MCRB Price Target Upside V Benchmarks

TypeNameUpside
StockSeres Therapeutics-92.72%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$17.17$17.17$17.17
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-22--4
Sep, 25-22--4
Aug, 25-22--4
Jul, 25-22-15
Jun, 25-22-15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 07, 2024Keay NakaeChardan Capital$1.25$0.8547.06%-92.72%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 12, 2024Cowen & Co.BuyBuyhold
Jun 07, 2024OppenheimerOutperformPerformdowngrade
May 09, 2024OppenheimerOutperformOutperformhold
Mar 06, 2024Chardan CapitalBuyBuyhold
Apr 28, 2023Chardan CapitalBuyBuyhold
Sep 07, 2022Piper SandlerOverweightOverweighthold
Jun 08, 2022JefferiesBuyupgrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.08$-0.67$-2.35$-0.89-----
Avg Forecast$-1.10$-0.62$-2.16$-0.99$-0.12$-0.33$-0.37$-0.29$-0.70
High Forecast$-1.10$-0.62$-2.16$-0.91$-0.03$-0.15$0.05$0.05$-0.70
Low Forecast$-1.10$-0.62$-2.16$-1.08$-0.30$-0.43$-0.76$-0.62$-0.70
Surprise %-1.82%8.06%8.80%-10.10%-----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$33.22M$144.93M$7.13M$126.33M-----
Avg Forecast$22.59M$149.82M$13.76M$126.07M$31.00M$33.08M$25.00M$125.00M$296.16M
High Forecast$22.59M$149.82M$13.76M$126.43M$31.00M$33.08M$25.00M$125.00M$296.16M
Low Forecast$22.59M$149.82M$13.76M$125.93M$31.00M$33.08M$25.00M$125.00M$296.16M
Surprise %47.01%-3.27%-48.18%0.20%-----

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-86.45M$-61.50M$-253.82M$-113.72M$136.00K----
Avg Forecast$-141.12M$-78.79M$-276.97M$-126.94M$-20.81M$-37.00M$-45.12M$-55.04M$-90.22M
High Forecast$-141.12M$-78.79M$-276.97M$-115.98M$-3.64M$-18.88M$6.94M$6.42M$-90.22M
Low Forecast$-141.12M$-78.79M$-276.97M$-137.89M$-37.98M$-55.12M$-97.19M$-79.61M$-90.22M
Surprise %-38.74%-21.95%-8.36%-10.41%-100.65%----

MCRB Forecast FAQ

Is Seres Therapeutics stock a buy?

Seres Therapeutics stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 3 Hold, 4 Sell, and 0 Strong Sell, reflecting a consensus that Seres Therapeutics is a favorable investment for most analysts.

What is Seres Therapeutics's price target?

Seres Therapeutics's price target, set by 18 Wall Street analysts, averages $1.25 over the next 12 months. The price target range spans from $1.25 at the low end to $1.25 at the high end, suggesting a potential -92.72% change from the previous closing price of $17.17.

How does Seres Therapeutics stock forecast compare to its benchmarks?

Seres Therapeutics's stock forecast shows a -92.72% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Seres Therapeutics over the past three months?

  • October 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Seres Therapeutics’s EPS forecast?

Seres Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.33, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $-0.37 in 2026, $-0.29 in 2027, and $-0.7 in 2028.

What is Seres Therapeutics’s revenue forecast?

Seres Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $33.08M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $25M, followed by $125M for 2027, and $296.16M for 2028.

What is Seres Therapeutics’s net income forecast?

Seres Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-36.997M, representing a -27303.52% decrease from the reported $136K in 2024. Projections indicate $-45.124M in 2026, $-55.039M in 2027, and $-90.217M in 2028.